Abstract
Background: Growth differentiation factor 15 (GDF-15) is a strong prognostic marker in sepsis and cardiovascular disease (CVD). The prognostic value of GDF-15 in coronavirus disease 2019 (COVID-19) is unknown.
Methods: Consecutive, hospitalized patients with laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and symptoms of COVID-19 were enrolled in the prospective, observational COVID Mechanisms Study. Biobank samples were collected at baseline, day 3 and day 9. The primary end point was admission to the intensive care unit or death during hospitalization, and the prognostic performance of baseline and serial GDF-15 concentrations were compared with that of established infectious disease and cardiovascular biomarkers.
Results: Of the 123 patients enrolled, 35 (28%) reached the primary end point; these patients were older, more often had diabetes, and had lower oxygen saturations and higher National Early Warning Scores on baseline. Baseline GDF-15 concentrations were elevated (>95th percentile in age-stratified healthy individuals) in 97 (79%), and higher concentrations were associated with detectable SARS-CoV-2 viremia and hypoxemia (both P <0.001). Patients reaching the primary end point had higher concentrations of GDF-15 (median, 4225 [IQR, 3197-5972] pg/mL versus median, 2187 [IQR, 1344-3620] pg/mL, P <0.001). The area under the receiver operating curve was 0.78 (95% CI, 0.70-0.86). The association between GDF-15 and the primary end point persisted after adjusting for age, sex, race, body mass index, estimated glomerular filtration rate, previous myocardial infarction, heart failure, and atrial fibrillation ( P <0.001) and was superior and incremental to interleukin-6, C-reactive protein, procalcitonin, ferritin, D-dimer, cardiac troponin T, and N-terminal pro-B-type natriuretic peptide. Increase in GDF-15 from baseline to day 3 was also greater in patients reaching the primary end point (median, 1208 [IQR, 0-4305] pg/mL versus median, -86 [IQR, -322 to 491] pg/mL, P <0.001).
Conclusions: GDF-15 is elevated in the majority of patients hospitalized with COVID-19, and higher concentrations are associated with SARS-CoV-2 viremia, hypoxemia, and worse outcome. The prognostic value of GDF-15 was additional and superior to established cardiovascular and inflammatory biomarkers. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04314232 .
Keywords: biomarkers; cardiovascular disease; coronavirus; growth differentiation factor 15; risk.
【저자키워드】 coronavirus, Biomarkers, risk, cardiovascular disease, growth differentiation factor 15, 【초록키워드】 COVID-19, coronavirus disease, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, Coronavirus disease 2019, coronavirus, Biomarkers, intensive care, Hospitalization, Infection, intensive care unit, interleukin-6, peptide, Sex, C-reactive protein, risk, cardiovascular disease, D-dimer, ferritin, procalcitonin, oxygen, Sepsis, Infectious disease, diabetes, outcome, hospitalized patients, severe acute respiratory syndrome Coronavirus, cardiac troponin, COVID, heart failure, Registration, Atrial fibrillation, Biobank, body mass index, interleukin, Viremia, Hypoxemia, Patient, death, Prognostic marker, troponin T, age, Myocardial infarction, prognostic, respiratory, Admission, score, association, glomerular filtration rate, inflammatory biomarkers, Concentration, filtration rate, body mass, cardiac troponin T, CVD, Prognostic value, acute respiratory syndrome, Older, estimated glomerular filtration rate, 95% CI, acute respiratory syndrome coronavirus, growth, healthy individuals, primary end point, symptoms of COVID-19, N-terminal pro-B-type natriuretic peptide, lower oxygen saturation, laboratory-confirmed, N-terminal, greater, enrolled, collected, detectable, elevated, median, increase, majority, hospitalized patient, reached, baseline, patients hospitalized, pro-B-type natriuretic peptide, with COVID-19, 【제목키워드】 COVID-19, cardiovascular, differentiation, Factor, Superior,